News | June 09, 2026
Wegovy pill smashes past 3mn prescriptions in under six months in US
The company said Wegovy hit its first one million prescriptions within 12 weeks of availability
The company said Wegovy hit its first one million prescriptions within 12 weeks of availability
The results come from post-hoc analyses of more than 1,500 women enrolled in the Phase 3 ATTAIN-1 and ATTAIN-2 trials, presented at the American Diabetes Association’s 86th Scientific Sessions
Researchers say the results point to a potential shift in how obesity is treated—as a central disease driving multiple conditions, rather than a collection of separate problems
The newly commissioned facility strengthens the ’company’s capabilities in the development and manufacturing of generic and complex sterile injectable products
Targeting deadly drug-resistant acinetobacter infections
Following the completion of the acquisition on June 3, Noctrix’s flagship product, Nidra will become part of ResMed’s broader sleep medicine portfolio
First-in-class treatment of life-threatening, drug-resistant Acinetobacter baumannii infections advancing toward Phase II clinical proof-of-concept
This facility plays an important role in Granules’ global manufacturing and supply network
Anti-GD2 monoclonal antibody for high-risk neuroblastoma advances toward BLA submission following successful tech transfer from California to Bengaluru
Approved as a web-based pre-diagnostic tool for suspected rare diseases and classified as a Class A (non-sterile and non-measuring) medical device
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
